Cipla USA Inc., a wholly-owned subsidiary of Indian pharmaceutical and biotechnology major Cipla Ltd, has acquired worldwide rights to a prescription drug from United States pharmaceutical company Achaogen Inc..
The drug, Zemdri, was acquired from Achaogen as part of an auction of its assets under Chapter 11 of the US Bankruptcy Code. The drug is an intravenous medicine used for the treatment of complicated urinary tract infections in adults who are unresponsive to other available options. The financial details of the transaction were not disclosed.
Cipla USA will hold the worldwide rights (excluding Greater China) to Zemdri along with its allied assets and liabilities, the firm said in a statement. The drug was approved by the US Food & Drug Administration in June last year, and launched shortly after that. It has also been filed for approval in the European Union.
South Africa Today
Read more at VolaNews
